ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
71,449.41
7.81%
S&P 500
5,308.13
0.09%
Dow Jones
39,806.77
-0.49%
US Dollar vs Yen
156.3785
0.40%
Brent Oil
83.53
-0.08%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Arrowhead Pharmaceuticals Inc (ARWR)

  7. Arrowhead Pharmaceuticals Inc (ARWR) ニュース

ARWR

Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:ARWR
日付受信時刻ニュースソース見出しコード企業名
2024/05/1005 : 11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/05/0707 : 04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/04/1622 : 00GlobeNewswire Inc.Turnstone Biologics Appoints William Waddill to its Board of DirectorsNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/03/0907 : 54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/03/0707 : 30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/02/2807 : 08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/02/0706 : 13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/02/0706 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/02/0307 : 25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/02/0106 : 57Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/2707 : 28Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/1808 : 32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/1807 : 22Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/1708 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/1708 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/1708 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/1708 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/1306 : 16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/1206 : 48Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/1206 : 38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/1206 : 22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/1206 : 05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/0907 : 17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/0907 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/0907 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/0610 : 02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/0609 : 58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/0607 : 33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/0607 : 14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
2024/01/0606 : 58Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ARWR

最近閲覧した銘柄

NYSE
NKE
Nike
USOTC
BNPQY
BNP Paribas (QX)
USOTC
ADDYY
Adidas (QX)
CCOM
SILVER
SILVER
SPI
SP500
S&P 500
CCOM
US30
US 30
COIN
BTCUSD
Bitcoin
AMEX
SPY
SPDR S&P 500
NASDAQ
AMZN
Amazon.com
USOTC
RHHBY
Roche (QX)
AMEX
XLE
Energy Select Sector SPDR
NYSE
DIS
Walt Disney
NASDAQ
NVDA
NVIDIA
CCOM
US500
US 500
NYSE
JPM
JP Morgan Chase
FX
USDEUR
US Dollar vs Euro
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有